Onc Daily: COVID-19 Impedes Cancer Trials, Bladder Cancer Study Onc Daily: COVID-19 Impedes Cancer Trials, Bladder Cancer Study
Here are the most important stories that Medscape Oncology's editors picked for you to read today.Medscape Medical News
Conclusions: Our report is the first study to examine the distant metastatic breast cancer proteome using FFPE tissues. The depth of our dataset allowed us to discover a novel biomarker candidate and a proteomic characteristics of distant metastatic breast cancer. Distinct molecular features of various breast cancer subtypes were also established. Our proteomic data constitute a valuable resource for research on distant metastatic breast cancer. PMID: 32489334 [PubMed]
Publication date: May 2020Source: Membrane Technology, Volume 2020, Issue 5Author(s):
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
On April 20, the president calls a press conference to announce a breakthrough in the fight against COVID-19. It’s a new use for an old malaria treatment, he says, one that is seeing miraculous results among the country’s most ill patients. It’s so safe that even schoolchildren could take it. In fact, he urges them to do so daily, as a preventative. He admits that he, too, is taking the medicine. No, this is not the President of the United States touting an unproven remedy for a virus that has infected nearly 5 million people worldwide. It is Madagascar’s President Andry Rajoelina, who is just as wi...
(IOS Press) Bladder cancer is associated with significant illness and mortality, particularly if treatment is delayed. Writing in the journal Bladder Cancer, researchers have outlined recommendations for treatment of both muscle invasive (MIBC) and non-muscle invasive (NMIBC) bladder cancer during the COVID-19 pandemic based on data from trials and prior studies, and taking into account the current strains on the healthcare system.
CONCLUSION: The joint functional urology committees indicate that there are specific clinical situations in this field that demand non-delayed care during COVID crisis. They underline the need to establish a hierarchy for the cancelled surgeries, in order to reduce the arm of long reschedule delays and to optimize post-lockdown activity resumption. PMID: 32418734 [PubMed - as supplied by publisher]
Tushar A Narain, Gagan Gautam, Amlesh Seth, Vikas K Panwar, Sudhir Rawal, Puneet Dhar, Harkirat S Talwar, Amitabh Singh, Jiten Jaipuria, Ankur MittalIndian Journal of Cancer 2020 57(2):129-138 The Corona Virus Disease-2019 (COVID-19), one of the most devastating pandemics ever, has left thousands of cancer patients to their fate. The future course of this pandemic is still an enigma, but health care services are expected to resume soon in a phased manner. This might be a long drawn process and we need to have policies in place, to be able to fight both, the SARS-CoV-2 virus and cancer, simultaneously, and emerge triumphan...
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post Could BCG, a 100-year-old Vaccine for Tuberculosis, Protect Against Coronavirus? appeared first on Inter Press Service.
Publication date: Available online 24 April 2020Source: European UrologyAuthor(s): Lenfant Louis, Seisen Thomas, Loriot Yohann, Rouprêt Morgan
Publication date: Available online 27 April 2020Source: European UrologyAuthor(s): Valeria Panebianco, Francesco Del Giudice, Costantino Leonardo, Alessandro Sciarra, Catalano Catalano, James W.F. Catto